妊娠35-37周子痫前期的筛查
这项前瞻性观察研究纳入13350例单胎妊娠,在35+0至36+6周联合母体因素与MAP、PlGF、sFlt-1等标志物筛查子痫前期。在1/20风险截断值下,母体因素联合MAP、PlGF和sFlt-1对后续发生子痫前期的检出率为70%,加用UtA-PI未提高筛查效能,筛查效能随种族起源而异。
要点
- 35-37周筛查时,母体因素联合MAP、PlGF和sFlt-1对后续子痫前期的检出率为70%,加用UtA-PI未进一步提高。
- 1/20风险截断值下约10%人群被划为高风险,母体因素单独筛查检出率为28%。
- 筛查效能随种族起源不同:白种女性检出率66%、筛查阳性率9.5%,非裔加勒比女性分别为88%和18%。
核心结论
- 在35-37周联合母体因素与生物标志物筛查可识别后续发生晚发型子痫前期的大部分妊娠,筛查效能取决于女性种族起源。
研究设计与样本
- 前瞻性观察研究,纳入13350例单胎妊娠,于35+0至36+6周常规孕期超声检查时入组,采用贝叶斯定理结合母体特征与病史得出的分娩时子痫前期先验分布与各生物标志物中位数倍数(MoM)值计算个体化风险。
诊断标准与关键数值
- 发生子痫前期的妊娠中MAP、UtA-PI和sFlt-1的MoM值升高、PlGF MoM降低;风险截断值1/20时约10%人群被划为高风险,母体因素单独筛查检出率28%,加MAP为53%,加MAP和PlGF为67%,加MAP、PlGF和sFlt-1为70%。
临床应用与阅片要点
- 筛查采用母体因素联合MAP、PlGF和sFlt-1可在35-37周识别后续发生晚发型子痫前期的高风险妊娠,加用UtA-PI未改善筛查效能;解读风险时需考虑种族起源对检出率和筛查阳性率的影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To examine the performance of screening for pre-eclampsia (PE) at 35-37 weeks' gestation by maternal factors and combinations of mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), serum placental growth factor (PlGF) and serum soluble fms-like tyrosine kinase-1 (sFlt-1).
METHODS: This was a prospective observational study in women with singleton pregnancy attending for an ultrasound scan at 35 + 0 to 36 + 6 weeks as part of routine pregnancy care. Bayes' theorem was used to combine the prior distribution of gestational age at delivery with PE, obtained from maternal characteristics and medical history, with various combinations of biomarker multiples of the median (MoM) values to derive the patient-specific risks of delivery with PE. The performance of such screening was estimated.
RESULTS: The study population of 13 350 pregnancies included 272 (2.0%) that subsequently developed PE. In pregnancies that developed PE, the MoM values of MAP, UtA-PI and sFlt-1 were increased and PlGF MoM was decreased. At a risk cut-off of 1 in 20, the proportion of the population stratified into high risk was about 10% of the total, and the proportion of cases of PE contained within this high-risk group was 28% with screening by maternal factors alone; the detection rate increased to 53% with the addition of MAP, 67% with the addition of MAP and PlGF and 70% with the addition of MAP, PlGF and sFlt-1. The performance of screening was not improved by the addition of UtA-PI. The performance of screening depended on the racial origin of the women; in screening by a combination of maternal factors, MAP, PlGF and sFlt-1 and use of the risk cut-off of 1 in 20, the detection rate and screen-positive rate were 66% and 9.5%, respectively, for Caucasian women and 88% and 18% for those of Afro-Caribbean racial origin.
CONCLUSION: Screening by maternal factors and biomarkers at 35-37 weeks' gestation can identify a high proportion of pregnancies that develop late PE. The performance of screening depends on the racial origin of the women. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Panaitescu A, Ciobanu A, Syngelaki A, et al. Screening for pre-eclampsia at 35-37 weeks' gestation. Ultrasound Obstet Gynecol. 2018. PMID: 29896778. doi:10.1002/uog.19111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。